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Between 2000 and 2012, malaria incidence rates were reduced
by 29% globally, and by 31% in the WHO African Region. The global
malaria mortality rate was reduced by 45% during the same period,
while the decrease in the WHO African Region was 49%. While this
progress is unprecedented, malaria still kills over 600,000 people
and results in more than 200 million cases every year. While cur-
rent interventions and strategies remain effective and save lives
in most settings, they entail high long-term costs and are threat-
ened by drug and insecticide resistance. New interventions and
new strategies are needed for accelerating the pathway to erad-
ication and the best way to sustain the progress gained by high
level control and toprevent resurgence. Investments leading tonew
insights and innovations in the science of eradication and ﬂexible
delivery models can help speed the trajectory to malaria eradica-
tion by detecting and eliminating the human reservoir of infection
in asymptomatic persons combined with effective and complete
transmission prevention. While sustaining current gains is imper-
ative, a new emphasis on achieving the goal of eradication is vital
today.
http://dx.doi.org/10.1016/j.ijid.2014.03.442
Type: Invited Presentation
Final Abstract Number: 05.002
Session: Grand Challenges in Malaria
Date: Thursday, April 3, 2014
Time: 10:15-12:15
Room: Room 2.40
Preventing the global spread of artemesinin
resistance: Can we subvert evolution?
P. Guerin
WorldWide Antimalarial Resistance Network
(WWARN), Oxford, United Kingdom
In virtually all countries, Plasmodium falciparum malaria is
treatedwithanACT, a combinationof artemisininwitha longacting
partnerdrug.Antimalarial drug resistance, inparticular artemisinin
resistance is now conﬁrmed in Cambodia, Thailand, Laos, Vietnam
and Myanmar. If this resistance were to spread westward, and this
trait becomes common in Africa, the result will be a global public
health catastrophe. It would derail current control and elimination
efforts and reverse achievements made in the last decade.
Historically resistance has been identiﬁed only when it rose to
levels that causedmany treatment failures. The “standard” reaction
was to shift to the next drug, from chloroquine to sulfadoxine-
pyrimethamine, for example. While this tactic was possible in the
past, development of a new antimalarial, registration, change of
policies, and necessary training to support a new national treat-
ment guideline will take years if not decades. Therefore all efforts
must be made to prolong the therapeutic life of the ACTs.
A very aggressive strategy will be needed to eliminate resis-
tant parasites in the Greater Mekong region with the current tools
available. It should include innovative approaches such as mass
drug administration, targeted strategies on speciﬁc populations,
and improvement of drug quality. This targeted strategy must be
guided by up to date intelligence on clinical response and on active
mapping of the spread of resistance.
Many of the antimalarial regimens have been developed and
recommended for “standard patients”, while in real life, a large
fraction of the beneﬁciaries do not ﬁt into this category. Outside the
resistancezone, theunderlying factorsdriving resistance, i.e. inade-
quate drug dosage, drug interaction, drug quality, pharmacological
responses in particular sub-population like small infants, pregnant
women, undernourished, co-infected patients must be studied and
addressed now. If we want to have a chance of cheating evolution
and preventing the inevitable, stakeholdersmust be ready to invest
and rapidly adjust their strategy in the war against resistance and
malaria.
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